Germany's CureVac says low-dose coronavirus vaccine could allow for mass production [Yahoo! Finance News]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance News
TUEBINGEN, Germany, March 13 ) - Germany's CureVac, among the vaccine developers funded by the Coalition for Epidemic Preparedness Innovations CEPI), said it could mass-produce a coronavirus immunisation from its existing facilities if its low-dose approach proves successful in trials. Privately held Curevac, which was granted up to $8.3 million by CEPI in January, is working to draw on its low-dose vaccine technology, which has showed promise in an early-stage rabies trial, for use against the coronavirus. The Tuebingen, Germany, based company hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans. Florian von der Muelbe, Chief Production Officer and co-founder, told a mode of action that allowed for a low dosage to trigger an immune reaction against rabies would also be applied in the coronavirus setting. "These minimal dosages that we have achieved put us in a position here in Tuebingen to produce up to 10 millio
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive YearAccesswire
- Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an "overweight" rating on the stock.MarketBeat
- Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
- Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and OlderAccesswire
MRNA
Earnings
- 11/7/24 - Beat
MRNA
Sec Filings
- 11/12/24 - Form 4
- 11/12/24 - Form 144
- 11/7/24 - Form 10-Q
- MRNA's page on the SEC website